Sildenafil Tablet, Film Coated
Product Images NDC 68071-3908

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 68071-3908). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3908 1)

Label for Sildenafil 100 mg film-coated tablets in a package of 10 tablets by NuCare Pharmaceuticals, Inc. The label includes the NDC 68071-3908, tablet description as diamond shaped and biconvex, and dosage instructions. Manufactured by Aurobindo Pharma Limited, India. The label states Rx Only and storage temperature instructions.*

FDA Label Image

Figure 1 (Sildenafil Fig1)

A line graph depicting the mean change from baseline in sitting systolic blood pressure over 24 hours post-dose in healthy volunteers. The graph compares Sildenafil 100 mg and Placebo, showing systolic blood pressure changes in mmHg on the y-axis and time post dose in hours on the x-axis. Two distinct lines with markers represent the two groups.*

FDA Label Image

Figure 2 (Sildenafil Fig2)

A line graph titled 'Mean Standing Systolic Blood Pressure Change from Baseline' showing change in SBP (mmHg) on the vertical axis and time postdose (hours) on the horizontal axis. It compares two groups: Doxazosin + Placebo and Doxazosin + Sildenafil 25 mg, over an 8-hour period, illustrating variations in systolic blood pressure postdose.*

FDA Label Image

Figure 3 (Sildenafil Fig3)

Line chart titled 'Mean Standing Systolic Blood Pressure Change from Baseline' showing change in SBP (mmHg) over 8 hours postdose. It compares two groups: Doxazosin + Placebo and Doxazosin + Sildenafil 50 mg, with SBP changes plotted on the y-axis and time in hours on the x-axis.*

FDA Label Image

Figure 4 (Sildenafil Fig4)

A line graph showing the mean standing systolic blood pressure change from baseline over time after dosing (hours). The graph compares two groups: one receiving Doxazosin plus Sildenafil 100 mg and the other Doxazosin plus Placebo, with mmHg on the vertical axis and time in hours (0 to 8) on the horizontal axis.*

FDA Label Image

Figure 5 (Sildenafil Fig5)

A line graph depicting mean Sildenafil plasma concentrations (ng/mL) over time post-dose (hours) in healthy male volunteers. The x-axis represents time from 0 to 24 hours, and the y-axis shows plasma concentrations from 0 to 500 ng/mL. Data points with error bars illustrate concentration decline following a commercial tablet dose.*

FDA Label Image

Figure 6. Effect Of Sildenafil And Placebo On Maintenance Of Erection By Baseline Score (Sildenafil Fig6)

Two bar charts titled 'Effect of Sildenafil on Maintenance of Erection by Baseline Score' and 'Effect of Placebo on Maintenance of Erection by Baseline Score.' Both show percentages of patients at endpoint across baseline scores 0 to 5, with multiple bars per score representing different categories indicated by a legend with values 0 through 5.*

FDA Label Image

Sildenafile Fig 7 (Sildenafil Fig7)

A bar chart depicting the percentage of patients reporting improvement in erections by treatment group, including placebo and Sildenafil at 25 mg, 50 mg, and 100 mg doses. The chart shows increasing percentages of improvement with higher Sildenafil doses.*

FDA Label Image

Structure (Sildenafil Str)

Chemical structure of Sildenafil, showing its molecular composition with labeled atoms and bonds, including characteristic rings and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.